Teva Pharm expects about 25 pct of EpiPen market by year end
February 19, 2019 at 03:42 AM EST
Teva Pharmaceutical Industries expects its generic version of Mylan's EpiPen to have about 25 percent of the U.S. market by the end of 2019, Chief Executive Kare Schultz said on Tuesday.
